For the full year 2021, Ocaliva net sales were $363.5 million including USA net sales of $260.8 million, which represented growth of 16% as compared to the prior year
For the full year 2021, Ocaliva net sales were $363.5 million including USA net sales of $260.8 million, which represented growth of 16% as compared to the prior year
Intercept Pharmaceuticals Inc. has said it entered into a settlement agreement with Dr. Reddy’s Laboratories resolving the previously disclosed patent litigation to market a generic version of Ocaliva (obeticholic acid) 5 mg and 10 mg tablets in the USA.
Ocaliva is used to treat a rare, chronic liver disease known as primary biliary cholangitis (PBC).
“Under the terms of the agreement, Intercept granted Dr. Reddy’s a non-exclusive, non-sublicensable, non-transferable, royalty-free licence to commercialise its generic version of Ocaliva in the United States commencing on October 26, 2035, or earlier under certain circumstances,” Intercept Pharmaceuticals in a regulatory filing said.
Similar patent litigation, previously disclosed by the company against five other ANDA (Abbreviated New Drug Application) filers seeking approval to market generic Ocaliva, remains pending, it further said.
For the full year 2021, Ocaliva net sales were $363.5 million including USA net sales of $260.8 million, which represented growth of 16% as compared to the prior year.
In May 2020, Dr. Reddy’s said it has launched the generic version of Ocaliva in the Indian market.
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
